Drug intelligence / Profile preview

everolimus + carboplatin + cetuximab

Development stage: Unknown
Lead developer: Emory University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This combination therapy regimen, evaluated by Emory University's Winship Cancer Institute, consists of the mTOR inhibitor everolimus (RAD001), the platinum-based chemotherapeutic carboplatin, and the EGFR-targeting monoclonal antibody cetuximab. It was specifically investigated for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The rationale behind the combination is that mTOR inhibition may overcome resistance to EGFR inhibitors like cetuximab and enhance the antitumor efficacy of standard platinum-based chemotherapy. Clinical trials determined the maximum tolerated dose of everolimus within this triplet and observed encouraging clinical activity, including improved response rates and progression-free survival in patients with advanced SCCHN.

Brand names: AfinitorErbituxParaplatin
Other names: RAD001 + carboplatin + cetuximabEverolimus + Carboplatin + Cetuximab

Targets

Mechanistic target of rapamycin complex 1EGFR T790M (Epidermal growth factor receptor T790M mutant)DNA

Beyond the preview

Go deeper on everolimus + carboplatin + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on everolimus + carboplatin + cetuximab.

Explore the full profile